Source: Eur Respir J 2014; 43: 312-313
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Srivastava Shashikant, Gumbo Tawanda. Integrating drug concentrations and minimum inhibitory concentrations with Bayesian-dose optimisation for multidrug-resistant tuberculosis. Eur Respir J 2014; 43: 312-313

Member's Comments

No comment yet.

Related content which might interest you: Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains Source: Eur Respir J 2015; 45: 285-287 Year: 2015 Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains Source: Eur Respir J 2015; 45: 287-289 Year: 2015 Minimum inhibitory concentrations (MIC) determination of TB drugs and broad-spectrum antibiotics in M.tuberculosis with M/X/TDR Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Relationship between rpoB mutations and minimum inhibitory concentrations of rifampicin in multi drug resistant strains of mycobacterium tuberculosis Source: Annual Congress 2011 - Tuberculosis: from bench to bedside Year: 2011 Minimal inhibitory concentrations (MIC) of first line drugs in multidrug resistant strains of M. tuberculosis (MDR-TB) Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 The Glutoxim influence on minimum inhibitory concentration of isoniazid-resistant strains of Mycobacterium tuberculosis Source: International Congress 2019 – Tuberculosis: from basic science to patient care Year: 2019 Minimal inhibitory concentrations (MICs) of mefloquine: in vitro activity against MDR- and nonMDR-Tb strains Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Neuroleptic drugs as potential adjuvants in the treatment of MDR-TB: Minimal inhibitory concentrations (MICs) of different phenothiazines against M. tuberculosis Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Defining optimal fluoroquinolone exposure against Mycobacterium tuberculosis: contribution of murine studies Source: Eur Respir J, 57 (4) 2004315; 10.1183/13993003.04315-2020 Year: 2021 What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis? Source: Eur Respir J 2009; 34: 1492-1494 Year: 2009 Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis Source: Eur Respir J, 57 (4) 2004454; 10.1183/13993003.04454-2020 Year: 2021 Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300 mg linezolid dosages using in-house made capsules Source: Eur Respir J, 54 (6) 1900580; 10.1183/13993003.00580-2019 Year: 2019 Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2014; 43: 884-897 Year: 2014 Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance Source: Eur Respir J, 50 (1) 1700598; 10.1183/13993003.00598-2017 Year: 2017 A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis Source: Eur Respir J, 51 (2) 1702166; 10.1183/13993003.02166-2017 Year: 2018 The use of the lytic D29 mycobacteriophages for accelerated determination of the drug sensitivity of tuberculosis mycobacteria to first and second-line anti-TB drugs in clinical isolates obtained after initial cultivation Source: Virtual Congress 2020 – Tuberculosis: part 2 Year: 2020 Dependending on drug resistance character of bacteriostatic blood activity at time polychemotherapy against of M. tuberculosis strains isolated from patients Source: Eur Respir J 2002; 20: Suppl. 38, 613s Year: 2002 Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 Clinical and operational value of the extensively drug-resistant tuberculosis definition Source: Eur Respir J 2007; 30: 623-626 Year: 2007